Assembly Biosciences Inc

Assembly Biosciences Inc. is developing oral HBV‑curing drugs and microbiome therapies for CDAD, aiming to tackle hepatitis B and C. difficile with innovative biotech solutions.

Assembly Biosciences, a Nasdaq biotech firm, is pioneering oral drug platforms for a potential HBV cure and microbiome‑based CDAD therapy, offering breakthrough treatments for infectious diseases.

Assembly Biosciences Inc. continues to advance its innovative biopharmaceutical platforms targeting infectious diseases, such as Hepatitis B and Clostridium difficile-associated diarrhea, despite market fluctuations.

Assembly Biosciences Inc. is advancing innovative treatments for Hepatitis B virus and Clostridium difficile-associated diarrhea, positioning the company as a leader in infectious disease therapeutics.

Assembly Biosciences Inc. is advancing its innovative biopharmaceutical platforms to treat infectious diseases, including Hepatitis B and Clostridium difficile-associated diarrhea, with promising results and a strong market presence.

Assembly Biosciences Inc. is advancing its biopharmaceuticals, particularly in infectious diseases, with innovative platforms targeting Hepatitis B and Clostridium difficile, positioning the company for potential breakthroughs in patient care.